2.1
Durvalumab (Imfinzi, AstraZeneca) with tremelimumab (Imjudo, AstraZeneca) is indicated 'for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)'.
2 Information about durvalumab with tremelimumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for durvalumab and the summary of product characteristics for tremelimumab.
Price
2.3
The list price of durvalumab is £592.00 per 2.4‑ml vial and £2,466.00 per 10‑ml vial (excluding VAT; BNF online, accessed April 2025). The list price of tremelimumab is £20,610.00 per 15‑ml vial (excluding VAT; BNF online, accessed April 2025).
2.4
The company has a commercial arrangement. This makes durvalumab with tremelimumab available to the NHS with a discount. The size of the discount is commercial in confidence.
Carbon Reduction Plan
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on AstraZeneca's webpage on sustainability.